In 2016, the landmark phase III clinical trial, KEYNOTE-024, established immunotherapy as the first-line treatment for metastatic NSCLC with high PD-L1 expression without concomitant EGFR mutations or ALK rearrangements. This evidence concerns the gene EGFR and non-small cell lung carcinoma.